{"version":"company-facts.v1","source":"https://secwatch.observer","generated_at":"2026-06-03T09:35:34.757217+00:00","company":{"ticker":"AARD","cik":1774857,"company_name":"Aardvark Therapeutics, Inc."},"pagination":{"limit":100,"returned":2,"next_cursor":null},"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer","facts":[{"fact_type":"earnings_release","fact_key":"e0a0c8d29575bd0ef2b7d2d438a802f32e741e86","cik":1774857,"ticker":"AARD","company_name":"Aardvark Therapeutics, Inc.","filed_at":"2026-05-07T23:59:59+00:00","payload":{"eps_text":null,"guidance_signal":"none","item_codes_triggered":["2.02"],"net_income_text":"net loss of $21.6 million","period_text":"first quarter ended March 31, 2026","report_date":"2026-05-07","result_type":"reported_results","revenue_text":"$91.2 million"},"claim":"Aardvark Therapeutics, Inc. reported first quarter ended March 31, 2026 results: revenue $91.2 million, net income net loss of $21.6 million.","evidence_excerpt":"Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Updates ARD-101 and ARD-201 programs on voluntary pause; further guidance expected in Q2 2026 $91.2 million in cash, cash equivalents and short-term investments as of March 31, 2026, supports projected operations into mid-2027 SAN DIEGO, May 7, 2026 (GLOBE NEWSWIRE) -- Aardvark","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001193125-26-210664","anchor_url":"https://secwatch.observer/filing/0001193125-26-210664#claim-e0a0c8d29575bd0ef2b7d2d438a802f32e741e86","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1774857/000119312526210664/0001193125-26-210664-index.htm"},{"fact_type":"material_agreement","fact_key":"e9632d0abc292eaa2a0b483fd01276d201e881a0","cik":1774857,"ticker":"AARD","company_name":"Aardvark Therapeutics, Inc.","filed_at":"2026-03-24T23:59:59+00:00","payload":{"action":"entry","agreement_name":"Equity Distribution Agreement","agreement_type":"atm_program","counterparty":"Piper Sandler & Co.","effective_date":"2026-03-23","item_codes_triggered":["1.01"],"value_text":"up to $150,000,000"},"claim":"Aardvark Therapeutics, Inc. entered into Equity Distribution Agreement with Piper Sandler & Co. valued at up to $150,000,000 (effective 2026-03-23).","evidence_excerpt":"On March 23, 2026, Aardvark Therapeutics, Inc. (the “Company”) entered into an Equity Distribution Agreement (the “Equity Distribution Agreement”) with Piper Sandler & Co., as sales agent (the “Agent”), pursuant to which the Company may, from time to time, in its sole discretion, offer and sell through or to the Agent, shares (“Shares”) of its common stock, par value $0.00001 per share.","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001193125-26-120164","anchor_url":"https://secwatch.observer/filing/0001193125-26-120164#claim-e9632d0abc292eaa2a0b483fd01276d201e881a0","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1774857/000119312526120164/0001193125-26-120164-index.htm"}]}